Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

10.59 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.59
Bid (Size) 4.270 (1)
Ask (Size) 11.80 (1)
Prev. Close 10.59
Today's Range 10.59 - 10.59
52wk Range 10.49 - 28.80
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Clearside Biomedical Stock Gaining Today?
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace

Performance

YTD
-42.26%
-42.26%
1 Month
-22.76%
-22.76%
3 Month
-44.29%
-44.29%
6 Month
-27.81%
-27.81%
1 Year
-46.35%
-46.35%

More News

Read More
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
Via Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
Assessing Regenxbio: Insights From 4 Financial Analysts
Via Benzinga
Evaluating Regenxbio: Insights From 9 Financial Analysts
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Via Benzinga
Regenxbio: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
A Preview Of Regenxbio's Earnings
Via Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Via Benzinga
The One-Minute Market Report - Sunday, Feb. 11
Via Talk Markets
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
Via Benzinga
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.